This database contains 6 studies, archived under the term: "thiazoles"
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, Susanne,
Deptula, Dennis,
Thurfjell, Lennart,
Barkhof, Frederik,
Bohrmann, Bernd,
Brooks, David J.,
Klunk, William E.,
Ashford, Elizabeth,
Yoo, Kisook,
Xu, Zhi-Xin,
Loetscher, Hansruedi,
Santarelli, Luca
Background: Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD).; Objectives: To investigate whether treatment with gantenerumab leads to a measurable reduction in the level of Aβ amyloid in the brain and to elucidate the mechanism of amyloid reduction.; Design: A multicenter, randomized, double-blind, placebo-controlled, ascending-dose […]
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Rinne, Juha O.,
Brooks, David J.,
Rossor, Martin N.,
Fox, Nick C.,
Bullock, Roger,
Klunk, William E.,
Mathis, Chester A.,
Blennow, Kaj,
Barakos, Jerome,
Okello, Aren A.,
Rodriguez Martinez de Liano, Sofia,
Liu, Enchi,
Koller, Martin,
Gregg, Keith M.,
Schenk, Dale,
Black, Ronald,
Grundman, Michael
Background: Carbon-11-labelled Pittsburgh compound B ((11)C-PiB) PET is a marker of cortical fibrillar amyloid-beta load in vivo. We used (11)C-PiB PET to investigate whether bapineuzumab, a humanised anti-amyloid-beta monoclonal antibody, would reduce cortical fibrillar amyloid-beta load in patients with Alzheimer’s disease.; Methods: Patients with mild-to-moderate Alzheimer’s disease were randomly assigned to receive intravenous bapineuzumab or […]
Impact of molecular imaging on the diagnostic process in a memory clinic
Ossenkoppele, Rik,
Prins, Niels D.,
Pijnenburg, Yolande A.L.,
Lemstra, Afina W.,
van der Flier, Wiesje M.,
Adriaanse, Sofie F.,
Windhorst, Albert D.,
Handels, Ron L.H.,
Wolfs, Claire A.G.,
Aalten, Pauline,
Verhey, Frans R.J.,
Verbeek, Marcel M.,
van Buchem, Mark A.,
Hoekstra, Otto S.,
Lammertsma, Adriaan A.,
Scheltens, Philip,
van Berckel, Bart N.M.
Background: [(11)C]Pittsburgh compound B ([(11)C]PIB) and [(18)F]-2-fluoro-2-deoxy-D-glucose ([(18)F]FDG) PET measure fibrillar amyloid-β load and glucose metabolism, respectively. We evaluated the impact of these tracers on the diagnostic process in a memory clinic population.; Methods: One hundred fifty-four patients underwent paired dynamic [(11)C]PIB and static [(18)F]FDG PET scans shortly after completing a standard dementia screening. Two-year […]
In vivo assessment of amyloid-β deposition in nondemented very elderly subjects
Mathis, Chester A.,
Kuller, Lewis H.,
Klunk, William E.,
Snitz, Beth E.,
Price, Julie C.,
Weissfeld, Lisa A.,
Rosario, Bedda L.,
Lopresti, Brian J.,
Saxton, Judith A.,
Aizenstein, Howard J.,
McDade, Eric M.,
Kamboh, M. Ilyas,
DeKosky, Steven T.,
Lopez, Oscar L.
Objective: This study examined amyloid-β (Aβ) deposition in 190 nondemented subjects aged ≥82 years to determine the proportion of Aβ-positive scans and associations with cognition, apolipoprotein E (APOE) status, brain volume, and Ginkgo biloba (Gb) treatment.; Methods: Subjects who agreed to participate had a brain magnetic resonance imaging and positron emission tomography scan with (11) […]